title: High-grade gliomas.
abstract: OBJECTIVE
  This article reviews the standard treatment of patients with high-grade glioma primary brain tumors and discusses promising new therapeutic advances.
  
  
  RESULTS
  While surgery and radiation remain critical components of the management of patients with high-grade gliomas, chemotherapy has recently been proven to improve the overall survival of patients with glioblastomas and anaplastic oligodendrogliomas. Molecular markers are complementing clinical prognostic factors and, in some cases, are able to guide treatment decisions. Despite aggressive treatment, high-grade gliomas eventually progress, emphasizing the importance of continued development of novel therapies for the treatment of this deadly disease.
  
  
  CONCLUSIONS
  The care of patients with high-grade gliomas is challenging, but the experience is highly rewarding. Rapidly developing technology allows for the use of molecular data for improved classification of high-grade gliomas and is beginning to improve our understanding of the pathogenesis and drivers of this disease. Collaboration among investigators will be critical to effectively validate prognostic biomarkers and identify tumors that might benefit from specific therapies.
authors.forename: John F
authors.initials: JF
authors.lastname: de Groot
mesh_terms: D015415:Biomarkers / Q000097:blood; D001932:Brain Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005909:Glioblastoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D060787:Neoplasm Grading; D009837:Oligodendroglioma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers